Drawing for PENTEC HEALTH

USPTO serial 87753884

PENTEC HEALTH

Reviewed by CopyMark Law Group

Reg. 5852437Status 710
Filing date
Status date
Registration date
Sep 3, 2019
Examiner
EVANKO, PATRICIA MALESARDI
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with PENTEC HEALTH?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Allison Z. Gifford, Esq.

ALLISON Z. GIFFORD, ESQ. STRADLEY RONON STEVENS & YOUNG, LLP30 VALLEY STREAM PARKWAYMALVERN, PA 19355UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Vials containing compounded sterile preparations in the nature of sterile pharmaceutical preparations for the control of blood pressure, control of heart rate, for treatment of allergies, for treatment of anxiety, for treatment of apnea, for treatment of asthma, for treatment of bacterial infections, for treatment of diabetes, for treatment of electrolyte imbalance, for treatment of inflammations, for treatment of nausea and vomiting, for treatment of upper and lower gastrointestinal illness, for treatment of shock, for treatment of seizures, anesthetics for general use, sedatives, anti-coagulates, and for use in the inducement of labor; Syringes containing compounded sterile preparations in the nature of sterile pharmaceutical preparations for the control of blood pressure, control of heart rate, for treatment of allergies, for treatment of anxiety, for treatment of apnea, for treatment of asthma, for treatment of bacterial infections, for treatment of diabetes, for treatment of electrolyte imbalance, for treatment of inflammations, for treatment of nausea and vomiting, for treatment of upper and lower gastrointestinal illness, for treatment of shock, for treatment of seizures, anesthetics for general use, sedatives, anti-coagulates, and for use in the inducement of laborSECTION 8 - CANCELLEDNov 28, 2017
035Pharmaceutical services, namely, processing prescription drug orders in closed-door, sterile, compounding pharmacies; consulting services, namely, providing consumer information about health care plansSECTION 8 - CANCELLEDDec 31, 2007
036Providing information regarding health care claim insurance, claim information, and payment options to health care providers, insurers, and consumersSECTION 8 - CANCELLEDDec 31, 2007
041Educational services, namely, providing educational seminars to industry healthcare professionals in the field of care of patients suffering from end stage renal disease (ESRD), intractable pain, and spasticity conditionsSECTION 8 - CANCELLEDDec 31, 2007
044Pharmaceutical advice for renal clinics as well as pain and spasticity management physician practices; specialized closed-door, sterile pharmaceutical compounding services for renal and specialty infusion patients with implanted intrathecal pumpsSECTION 8 - CANCELLEDDec 31, 2007

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 13, 2026C8..CANCELLED SEC. 8 (6-YR)—
Sep 3, 2024REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Nov 25, 2020ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Sep 3, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 2, 2019SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Aug 1, 2019CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Jul 18, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 17, 2019SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Jul 17, 2019EX1GSOU EXTENSION 1 GRANTED—
Jul 17, 2019AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jul 15, 2019IUAFUSE AMENDMENT FILED—
Jul 15, 2019EXT1SOU EXTENSION 1 FILED—
Jul 15, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 15, 2019EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Jul 8, 2019DOCKASSIGNED TO EXAMINER—
Jun 5, 2019ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Jan 15, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Nov 20, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 20, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 31, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 2, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 26, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Sep 26, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Sep 26, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Sep 26, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 14, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 13, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 13, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 30, 2018GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Apr 30, 2018GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Apr 30, 2018CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Apr 24, 2018DOCKASSIGNED TO EXAMINER—
Jan 27, 2018MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Jan 26, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 16, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance